GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 53
- Registration Number
- NCT03739866
- Locations
- 🇺🇸
Orlando Immunology Center PA, Orlando, Florida, United States
🇺🇸Mills Clinical Research, Los Angeles, California, United States
🇺🇸The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 2
- Registration Number
- NCT03701438
- Locations
- 🇪🇸
Hospital Universitario Ramon y Cajal, Madrid, Spain
🇨🇿Fakultni nemocnice Kralovske Vinohrady, Interni hematologicka klinika, Prague 10, Czechia
Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 496
- Registration Number
- NCT03631732
- Locations
- 🇺🇸
Whitman-Walker Health, Washington, District of Columbia, United States
🇺🇸University Medical Center- New Orleans (UMCNO), New Orleans, Louisiana, United States
🇺🇸Georgetown University Hospital, Washington, District of Columbia, United States
Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 67
- Registration Number
- NCT03615066
- Locations
- 🇨🇦
University Health Network, Toronto General Hospital, Toronto Centre for Liver Disease, Toronto, Ontario, Canada
🇨🇦Toronto Liver Centre, Toronto, Ontario, Canada
🇰🇷Chung-Ang University Hospital, Seoul, Korea, Republic of
Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 112
- Registration Number
- NCT03582098
- Locations
- 🇬🇧
NHS Grampian, Aberdeen, United Kingdom
🇬🇧London Northwest University NHS Trust, Eastcote, United Kingdom
🇬🇧Cheltenham General Hospital, Cheltenham, United Kingdom
Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 201
- Registration Number
- NCT03580668
- Locations
- 🇨🇦
Spectrum Health, Vancouver, Canada
🇨🇦Regina General Hospital, Regina, Canada
🇨🇦Clinique Medicale du Quartier Latin, Montréal, Canada
Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 257
- Registration Number
- NCT03568929
- Locations
- 🇬🇷
University General Hospital of Alexandroupolis, Alexandroupolis, Greece
🇬🇷University General Hospital of Patras, Patra, Greece
🇧🇪Ziekenhuis Netwerk Antwerpen Stuivenberg Hospital, Antwerpen, Belgium
Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 34
- Registration Number
- NCT03558139
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 643
- Registration Number
- NCT03547973
- Locations
- 🇺🇸
The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults
- Conditions
- Interventions
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 244
- Registration Number
- NCT03547908
- Locations
- 🇪🇸
Hospital General Universitario de Valencia, Valencia, Spain
🇨🇳Taipei Veterans General Hospital, Taipei City, Taiwan
🇪🇸CHUVI - Hospital Universitario Alvaro Cunqueiro, Vigo, Spain